As reported by the National Institute of Science and Technology (NIST) www.nist.gov, bioelectronics medicine results from the convergence of neuroscience, molecular and cell biology, and bioengineering.
It is anticipated that one day bioelectronics medicine will use technology to treat disease and injury since the nervous system provides electrical signals to communicate information throughout the body.
Northwell Health’s Feinstein Institute for Medical Research www.feinsteininstitute.org recently announced an alliance with GE Ventures https://www.geventures.com to support Feinstein’s Center for Bioelectronic Medicine (CBEM).
GE Ventures support for CBEM will enable the Feinstein Institute to continue to develop and commercialize new diagnostic and therapeutic solutions in bioelectronics medicine. This support enables researchers to work on a wide range of acute and chronic diseases and injuries including neurodegenerative diseases, cancer, diabetes, and hypertension.
In forging another alliance, the Feinstein Institute and United Therapeutics Corporation www.unither.com have formed a strategic partnership to focus on the application of bioelectronics medicine and cell therapy as related to cardiology, hypertension, and post-transplant tolerance induction.
Under this strategic partnership, United Therapeutics will fund Northwell’s efforts in four research and development tracks and bring the results into clinical development. The two organizations are working towards attaining initial regulatory approvals within five years.
“Collaboration is the indispensable factor in successful medical research,” said Kevin J. Tracey MD, President and CEO of the Feinstein Institute. “With great partners, you can accomplish great things for science and for patients.”